16 February 2024
16 February 2024
Inventiva has paused enrolment for the Phase III trial investigating lanifibranor in NASH after an unexpected serious adverse event was reported in a patient.
Experts suggest taking caution when changing primary endpoints in active cancer clinical trials.
The trial will enrol 48 healthy individuals of the age 18 to 49 years in France.
Preclinical models have shown that ACOU085 has the potential to significantly reduce hearing loss caused by cisplatin.
The study will enrol up to 80 adults who are undergoing the surgical removal of two or more molar teeth.
Frexalimab was found to be well-tolerated in multiple sclerosis patients in the trial.
Osivax has vaccinated the first participant with the investigational sarbecovirus vaccine OVX033 in Paris, commencing the start of the 48-participant trial.
The FDA released guidance describing the eligibility criteria for companies to recover costs in lieu of access to investigational drugs in clinical studies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
